| Literature DB >> 32631309 |
Hongwei Shen1,2, Haochuan Chen2, Yongxuan Ou2, Tingting Huang1, Siping Chen1, Lintao Zhou3, Jinjin Zhang2, Qinghua Hu4, Yiwen Zhou1, Wen Ma5.
Abstract
BACKGROUND: Salmonella is one of the main causative agents of diarrhea which results in substantial disease burden. To determine the prevalence, serotype distribution, and antimicrobial resistance profiles of clinical Salmonella isolates in Shenzhen, a 6-year surveillance study was conducted.Entities:
Keywords: Antimicrobial resistance; Diarrhea; Prevalence; Salmonella; Serotype
Mesh:
Substances:
Year: 2020 PMID: 32631309 PMCID: PMC7339465 DOI: 10.1186/s12866-020-01886-5
Source DB: PubMed Journal: BMC Microbiol ISSN: 1471-2180 Impact factor: 3.605
The epidemiological and clinical characteristics of samples (n = 5239) in this study
| Category | Subcategory | No. (%) |
|---|---|---|
| Year | 2013 | 931 (17.8) |
| 2014 | 793 (15.1) | |
| 2015 | 652 (12.5) | |
| 2016 | 1285 (24.5) | |
| 2017 | 887 (16.9) | |
| 2018 | 691 (13.2) | |
| Age (years) | < 5 | 1361 (26.0) |
| 5 ~ 9 | 73 (1.4) | |
| 10 ~ 19 | 217 (4.1) | |
| 20 ~ 29 | 847 (16.2) | |
| 30 ~ 39 | 984 (18.8) | |
| 40 ~ 49 | 683 (13.0) | |
| 50 ~ 59 | 496 (9.5) | |
| > = 60 | 578 (11.0) | |
| Clinical Symptoms | Abdominal pain | 2098 (54.1) a |
| Fever | 310 (5.9) | |
| Vomiting | 635 (12.1) | |
| Blood in stools | 50 (1.0) |
aOnly 3878 cases aged over 5 years were included for analysis
The serotype distribution of clinical Salmonella isolates during 2013 and 2018
| Serotype | No. of isolates by year (recovery rate, %) | ||||||
|---|---|---|---|---|---|---|---|
| 2013 ( | 2014 ( | 2015 ( | 2016 ( | 2017 ( | 2018 ( | Total ( | |
| Typhimurium | 6 (0.6) | 8 (1.0) | 5 (0.8) | 58 (4.5) | 22 (2.5) | 19 (2.7) | 118 (2.3) |
| Enteritidis | 18 (1.9) | 6 (0.8) | 10 (1.5) | 12 (0.9) | 13 (1.5) | 12 (1.7) | 71 (1.4) |
| London | 2 (0.2) | 3 (0.4) | 2 (0.3) | 1 (0.1) | 4 (0.5) | 0 (0.0) | 12 (0.2) |
| 4, 5, 12: i: - | 0 (0.0) | 3 (0.4) | 0 (0.0) | 6 (0.5) | 0 (0.0) | 2 (0.3) | 11 (0.2) |
| Senftenberg | 1 (0.1) | 6 (0.8) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 1 (0.1) | 8 (0.2) |
| Stanley | 0 (0.0) | 3 (0.4) | 0 (0.0) | 1 (0.1) | 1 (0.1) | 2 (0.3) | 7 (0.1) |
| Agona | 3 (0.3) | 1 (0.1) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 1 (0.1) | 5 (0.1) |
| Litchfield | 0 (0.0) | 0 (0.0) | 5 (0.8) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 5 (0.1) |
| Weltevreden | 3 (0.3) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 1 (0.1) | 4 (0.1) |
| Others | 6 a (0.6) | 2 b (0.3) | 11 c (1.7) | 7 d (0.5) | 10 e (1.1) | 8 f (1.2) | 44 (0.8) |
| Un-typable | 4 (0.4) | 1 (0.1) | 1 (0.2) | 2 (0.2) | 3 (0.3) | 1 (0.1) | 12 (0.2) |
| Total | 43 (4.6) | 33 (4.2) | 34 (5.2) | 87 (6.8) | 53 (6.0) | 47 (6.8) | 297 (5.7) |
a Two strains of serotype Derby, 1 Ruzizi, 1 Meleagridis, and 2 Regent were included.
b One isolate of serotype Gallinarum-pullorum and 1 Drogana were included.
c One strain of Essen, 2 Manchester, 1 Sinstorf, 1 Chester, 1 Chomedey, 1 Tshiongwe, 1 Chennai, 1 Rissen, 1 Papuana, and 1 Fillmore were included.
d Two strains of serotype Virchow, 2 Nigeria, 1 Bovismorbificans, 1 Hidalgo, and 1 Amherstiana were included.
e Two strains of serotype Infantis, 1 Montevideo, 1 Bovismorbificans, 1 Chester, 2 Braenderup, 1 Kottbus, 1 Corvallis, and 1 Kentucky were included.
f One strain of serotype Rissen, 1 Hato, 1 Sarajane, 1 Chester, 1 Assinie, 1 Pomona, 1 Muenster, and 1 Vilvoorde were included.
The serotype distribution of clinical Salmonella isolates in different age groups
| Age group | No. of tested | No. of isolates (prevalence, %) | Total (%) | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Serotype | Serotype | Serotype | Serotype | Serotype | Serotype | Other | |||
| < 5 | 1361 | 87 (6.4) | 17 (1.2) | 8 (0.6) | 5 (0.4) | 1 (0.1) | 4 (0.3) | 15 (1.1) | 137 (10.1) |
| 5 ~ 9 | 73 | 4 (5.5) | 6 (8.2) | 1 (1.4) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 11 (15.1) |
| 10 ~ 19 | 217 | 0 (0.0) | 4 (1.8) | 0 (0.0) | 1 (0.5) | 1 (0.5) | 0 (0.0) | 3 (1.4) | 9 (4.1) |
| 20 ~ 29 | 847 | 7 (0.8) | 14 (1.7) | 0 (0.0) | 0 (0.0) | 3 (0.4) | 1 (0.1) | 11 (1.3) | 36 (4.3) |
| 30 ~ 39 | 984 | 9 (0.9) | 14 (1.4) | 0 (0.0) | 1 (0.1) | 2 (0.2) | 0 (0.0) | 22 (2.2) | 48 (4.9) |
| 40 ~ 49 | 683 | 3 (0.4) | 4 (0.6) | 1 (0.1) | 3 (0.4) | 1 (0.1) | 1 (0.1) | 11 (1.6) | 24 (3.5) |
| 50 ~ 59 | 496 | 3 (0.6) | 6 (1.2) | 1 (0.2) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 6 (1.2) | 16 (3.2) |
| > = 60 | 578 | 5 (0.9) | 6 (1.0) | 0 (0.0) | 2 (0.3) | 0 (0.0) | 1 (0.2) | 2 (0.3) | 16 (2.8) |
| total | 5239 | 118 (2.3) | 71 (1.4) | 11 (0.2) | 12 (0.2) | 8 (0.2) | 7 (0.1) | 70 (1.3) | 297 (5.7) |
Fig. 1The monthly distribution of clinical Salmonella isolates. PKUSZH, Peking University Shenzhen Hospital; SCH, Shenzhen Children’s Hospital; SYSU8H, The Eighth Affiliated Hospital, Sun Yat-Sen University
The antimicrobial susceptibility profiles of Salmonella isolates with different serotypes
| Antimicrobial agent | No. of resistant isolates by serotypes (resistant rate, %) | |||||
|---|---|---|---|---|---|---|
| Typhimurium | Enteritidis | London | Senftenberg | Others | Total | |
| ampicillin | 81 (95.3) | 22 (75.9) | 2 (40.0) | 0 (0.0) | 34 (48.6) | 139 (70.6) |
| piperacillin | 74 (87.1) | 21 (72.4) | 2 (40.0) | 0 (0.0) | 30 (42.9) | 127 (64.5) |
| ampicillin/ sulbactam | 9 (10.6) | 7 (24.1) | 0 (0.0) | 1 (12.5) | 6 (8.6) | 23 (11.7) |
| cefazolin | 50 (58.8) | 16 (55.2) | 1 (20.0) | 1 (12.5) | 19 (27.1) | 87 (44.2) |
| cefepime | 23 (27.1) | 5 (17.2) | 0 (0.0) | 0 (0.0) | 9 (12.9) | 37 (18.8) |
| cefotaxime | 40 (47.1) | 8 (27.6) | 0 (0.0) | 1 (12.5) | 15 (21.4) | 64 (32.5) |
| ceftriaxone | 42 (49.4) | 9 (31.0) | 0 (0.0) | 1 (12.5) | 14 (20.0) | 66 (33.5) |
| cefoxitin | 3 (3.5) | 2 (6.9) | 0 (0.0) | 1 (12.5) | 1 (1.4) | 7 (3.6) |
| ceftazidime | 13 (15.3) | 3 (10.3) | 0 (0.0) | 0 (0.0) | 7 (10.0) | 23 (11.7) |
| aztreonam | 23 (27.1) | 3 (10.3) | 0 (0.0) | 0 (0.0) | 9 (12.9) | 35 (17.8) |
| gentamicin | 22 (25.9) | 0 (0.0) | 3 (60.0) | 0 (0.0) | 13 (18.6) | 38 (19.3) |
| amikacin | 2 (2.4) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 2 (1.0) |
| streptomycin | 57 (67.1) | 20 (69.0) | 2 (40.0) | 1 (12.5) | 27 (38.6) | 107 (54.3) |
| imipenem | 3 (3.5) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 1 (1.4) | 4 (2.0) |
| meropenem | 2 (2.4) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 2 (1.0) |
| tetracycline | 81 (95.3) | 3 (10.3) | 2 (40.0) | 0 (0.0) | 39 (55.7) | 125 (63.5) |
| ciprofloxacin | 7 (8.2) | 2 (6.9) | 2 (40.0) | 0 (0.0) | 8 (11.4) | 19 (9.6) |
| levofloxacin | 5 (5.9) | 1 (3.4) | 0 (0.0) | 0 (0.0) | 6 (8.6) | 12 (6.1) |
| norfloxacin | 7 (8.2) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 3 (4.3) | 10 (5.1) |
| nalidixic acid | 26 (30.6) | 27 (93.1) | 3 (60.0) | 0 (0.0) | 18 (25.7) | 74 (37.6) |
| sulphamethoxazole/trimethoprim | 42 (49.4) | 4 (13.8) | 2 (40.0) | 1 (12.5) | 26 (37.1) | 75 (38.1) |
| trimethoprim | 38 (44.7) | 3 (10.3) | 2 (40.0) | 0 (0.0) | 22 (31.4) | 65 (33.0) |
| Chloramphenicol | 41 (48.2) | 2 (6.9) | 1 (20.0) | 0 (0.0) | 21 (30.0) | 65 (33.0) |
| nitrofurantoin | 2 (2.4) | 11 (37.9) | 0 (0.0) | 0 (0.0) | 8 (11.4) | 21 (10.7) |
| <0.08 | 0 (0.0) | 3 (10.3) | 2 (40.0) | 6 (72.5) | 23 (32.9) | 34 (17.3) |
| 0.08- | 3 (3.5) | 3 (10.3) | 0 (0.0) | 1 (12.5) | 5 (7.1) | 12 (6.1) |
| 0.13- | 5 (5.9) | 1 (3.4) | 1 (20.0) | 0 (0.0) | 3 (4.3) | 10 (5.1) |
| 0.17- | 10 (11.8) | 2 (6.9) | 0 (0.0) | 1 (12.5) | 5 (7.1) | 18 (9.1) |
| ≥0.21 | 67 (78.8) | 20 (69.0) | 2 (40.0) | 0 (0.0) | 34 (48.6) | 123 (62.4) |
The linkage of QRDRs mutations with antimicrobial susceptibility profile
| Isolate No. | Serotype | MAR | MIC (μg/ml) | Mutations-changes in codons | ||||
|---|---|---|---|---|---|---|---|---|
| CIP | LEV | |||||||
| 1 | Typhimurium | 0.33 | <=0.25 | <=0.12 | – | – | – | – |
| 2 | Typhimurium | 0.46 | 0.5 | 0.5 | – | – | – | – |
| 3 | Typhimurium | 0.63 | 1 | 2 | – | CTT → CT | GTT → GT | ACT→AC |
| 4 | Bovismorbificans | 0.38 | 1 | 0.5 | GAC → G | CTT → CT | – | ACT, CAC → CA |
| 5 | Typhimurium | 0.50 | 1 | 0.5 | GAC → G | CTT → CT | – | ACT, CAC → CA |
| 6 | Enteritidis | 0.33 | 0.5 | 2 | – | CTT → CT | – | ACT, CAC → CA |
| 7 | London | 0.33 | 1 | 1 | – | CTT → CT | GTT → GT | ACT, CAC → CA |
| 8 | Typhimurium | 0.33 | 2 | 1 | GAC → | – | – | – |
| 9 | Agona | 0.63 | 1 | 1 | – | CTT → CT | GTT → GT | ACT→AC |
| 10 | London | 0.42 | 1 | 1 | GAC → | CTT → CT | GTT → GT | – |
| 11 | Litchfield | 0.25 | 1 | 1 | GAC → | CTT → CT | – | – |
| 12 | 4, 5, 12, i: - | 0.21 | 1 | 1 | – | – | – | – |
| 13 | Enteritidis | 0.08 | 1 | 1 | GAC → | CTT → CT | – | ACT, CAC → CA |
| 14 | London | 0.13 | 2 | 0.5 | GAC → | CTT → CT | GTT → GT | ACT→AC |
| 15 | 4, 5, 12, i: - | 0.50 | 2 | 2 | GAC → | – | – | – |
| 16 | untypable | 0.42 | 2 | 4 | GAC → | – | – | – |
| 17 | 4, 5, 12, i: - | 0.42 | > = 4 | 4 | GAC → | – | – | – |
| 18 | Typhimurium | 0.42 | 2 | 2 | GAC → | – | – | – |
| 19 | Typhimurium | 0.63 | > = 4 | > = 8 | GAC → | – | – | – |
| 20 | Typhimurium | 0.46 | 2 | 4 | GAC → | – | – | – |
| 21 | Typhimurium | 0.58 | > = 4 | 4 | GAC → | – | – | – |
Base pair changes in bold type.
MIC minimum inhibitory concentration, CIP ciprofloxacin, LEV levofloxacin.
- No mutation
aAmino acid alteration is Asp-87 → Gly.
bAmino acid alteration is Asp-87 → Asn.
cAmino acid alterations are Leu-462 → Leu, Ser-464 → Ser.
dAmino acid alterations are Val-67 → Val, His-75 → His, His-77 → His, Ala-117 → Ala, Ser-123 → Ser.
eAmino acid alteration is Thr-500 → Thr.
fAmino acid alteration is His-509 → His.